tirzepatide trial results once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, tirzepatide clinical trial weight loss

Tirzepatide has two non-coded amino acid residues at positions 2 and 13 (Aib, -aminoisobutyric acid), and is acylated on K20 P (P indicates that the residue belongs to the peptide) with a Glu-2OEG linker and C18 fatty diacid moiety

Large database analyses from 2023 through 2025 have shown that patients on semaglutide and tirzepatide have lower incident rates of depression, anxiety, and suicidal ideation compared to matched controls on other diabetes medications

There is no robust evidence that enzyme supplements alleviate these specific Mounjaro-related side effects, as they are primarily driven by the drug's effect on gut motility and central appetite pathways rather than enzyme deficiency

0.90 (0.501.61) for cardiovascular death